



## Corrigendum to “Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma” [J. Interv. Med. 2 (2019) 21–26]



Yuanxun Yue<sup>a</sup>, Zhizhong Ren<sup>b</sup>, Ying Liu<sup>b</sup>, Yuewei Zhang<sup>b,\*</sup>

<sup>a</sup> Zhongshan Clinical College of Dalian University, Dalian, Liaoning Province, People's Republic of China

<sup>b</sup> Hepatobiliary Interventional Department, Beijing Tsinghua Chang Gung Hospital Affiliated to Tsinghua University, Beijing, People's Republic of China

The authors regret in this article published in Journal of Interventional Medicine, the current order of references is not correct, and the correct reference order is now attached.

- Bertino G, Demma S, Ardiri A et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. *Biomed Res Int*. 2015; 2015: 731469.
- Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. *Radiology*. 2012; 262(1):43–58.
- Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. *J Hepatol*. 2008; 48(suppl-1):S20–S37.
- Ayaru L, Pereira SP, Alisa A et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. *J Immunol*. 2007; 178(3):1914–1922.
- Mizukoshi E, Yamashita T, Arai K et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. *Hepatology*. 2013; 57(4):1448–1457.
- Mizukoshi E, Yamashita T, Arai K et al. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. *Cancer Immunol Immunother*. 2016; 65(6):715–725.
- Jin AO, Yue-Wei Z. Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research. *J Interv Radiol*. 2011; 18(3):229–234.
- Kamran AU, Liu Y, Li FE et al. Transcatheter arterial chemoembolization with gelatin sponge microparticles treated for BCLC stage B hepatocellular carcinoma: a single center retrospective study. *Medicine*. 2015; 94(52):e2154.
- Zhou J, Liu Y, Ren Z et al. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: initial clinical experience. *J Cancer Res Ther*. 2017; 13(5):767–772.
- Wu Q, Qin SK, Teng FM et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. *J Hematol Oncol*. 2010; 3(1):43.
- Wang N, Lv YZ, Xu AH et al. Application of lobaplatin in transcatheter arterial chemoembolization for primary hepatic carcinoma. *Asian Pac J Cancer Prev*. 2014; 15(2):647–650.
- Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. *Clin Canc Res Off J Am Assoc Canc Res*. 2013; 19(6):1312–1314.
- Dong W, An G, Xie S et al. The clinical and prognostic significance of CD14+HLA-DR-/low, myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. *Tumour Biol*. 2016; 37(8):10427–10433.
- Wan S, Kuo N, Kryczek I et al. Myeloid cells in hepatocellular carcinoma. *Hepatology*. 2015; 62(4):1304–1312.
- Bronte V, Brandau S, Chen SH et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun*. 2016; 7:12150–12159.
- Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol*. 2009; 9(3):162–174.
- Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. *Trends Immunol*. 2011; 32(1):19–25.
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol*. 2012; 12(4):253–268.

DOI of original article: <https://doi.org/10.1016/j.jimed.2019.05.006>.

\* Corresponding author.

E-mail address: [zhangyuewei1121@sina.com](mailto:zhangyuewei1121@sina.com) (Y. Zhang).

<https://doi.org/10.1016/j.jimed.2019.09.002>

19. Heimbach J, Kulik LM, Finn R et al. Aasld guidelines for the treatment of hepatocellular carcinoma. *Hepatology*. 2017; 67(1):358–380.
20. Omata M, Lesmana LA, Tateishi R et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int*. 2010; 4(2):439–474.
21. Han KH, Kudo M, Ye SL et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. *Oncology*. 2015; 81(Suppl.1):158–164.
22. Han Kichang, Kim Jin Hyoung. Transarterial chemoembolization in hepatocellular carcinoma treatment: barcelona clinic liver cancer staging system. *World J Gastroenterol*. 2015; 21(36):10327–10335.
23. Song L, Ran-Ran M, Yue-Wei Z. TACE combined with dendritic cells for the treatment of hepatic cancers: its influence on patient's immune function. *J Interv Radiol*. 2014; 23(2):181–184.
24. Zhi-Zhong R, Ying L, Yuan-Xun Y et al. Postoperative changes and its significance of Treg cells in peripheral blood after GSMs- TACE treatment for large hepatocellular carcinoma in 15 patients. *J Interv Radiol*. 2018; 27(12):1151–1154.
25. Chang CJ, Yang YH, Chiu CJ et al. Targeting tumor-infiltrating Ly6G+myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. *Int J Cancer*. 2018; 142(9):1878–1889.
26. Jiang N, Xing YF, Hu B et al. Endoplasmic reticulum stress induced Lox-1+CD15+polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma. *Immunology*. 2017; 154(1):144–155.
27. Weber R, Fleming V, Hu X et al. Myeloid-derived suppressor cells hinder the anticancer activity of immune checkpoint inhibitors. *Front Immunol*. 2018; 9:1310–1318.
28. Guo B, Xie N, Wang Y. Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis. *Bull Du Canc*. 2015; 102(3):204–212.
29. Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)/CD25(+)/Foxp3(+) T cells. *Gastroenterology*. 2008; 135(1):234–243.
30. Moehler M, Göpfert K, Outlook Lenz HJ. Immunotherapy in gastrointestinal carcinoma - innovative strategies. *Oncol Res Treat*. 2018; 41(5):313–315.

The authors would like to apologise for any inconvenience caused.